Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
about
Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthroughAdditional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthroughAcid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoringRefractory chronic cough due to gastroesophageal reflux: Definition, mechanism and management.Recommendations for the management of cough in adults.A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough.Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough: a Cochrane systematic review.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.Review article: treatment of mild and severe cases of GERD.Review article: management of mild and severe gastro-oesophageal reflux disease.Pharmacogenomics of proton pump inhibitors.Non-pharmacologic treatment strategies in gastroesophageal reflux disease.Review article: diagnosis and management of night-time reflux.Nocturnal acid breakthrough - approach to management.Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitudeReview article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure.Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.Review article: acid-related disease--what are the unmet clinical needs?Review article: the opportunities and benefits of extended acid suppression.Acid suppressive therapy use on an inpatient internal medicine service.Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor TherapyOptimal treatment of laryngopharyngeal reflux disease.Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease.Symptoms and esophageal motility based on phenotypic findings of scleroderma.Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A ReviewIndividualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Histamine-2 Receptor Antagonists and Semen Quality.Yield of combined impedance-pH monitoring for refractory reflux symptoms in clinical practice.Can Nocturnal Acid-breakthrough Be Reduced by Long-acting Proton Pump Inhibitors?Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule.Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity.Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey.Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy.Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease.
P2860
Q24240662-E879CEDF-C5B3-4A3F-BC19-40236FF4ECA2Q24246606-C9E9816B-CC30-41EB-9ACB-3A5304BA696DQ24679917-50546648-45CB-4287-B463-C70C5776ED29Q26785656-CF8BC371-C5D5-4682-A51A-3DA05421EBC4Q28260345-B9EEDCC9-D92A-4380-B570-279A2BA97288Q30390631-79F01A6F-4833-42A8-956E-23931D9B89DEQ33248384-B6EBC075-42B3-40F2-A3D0-486F3045AB34Q34583603-4947ADBA-23DA-4351-9A97-2743B4802EFCQ34669262-4FCAF2CC-6F85-4F2A-89A8-FF8E9927982CQ35145033-F906AB38-418F-4D69-98F6-725584F4498DQ35689146-0DA8E3B2-0000-481B-9EBC-F2F758DDE12EQ35868517-615B5D6A-FC67-4016-A24A-0CADDA805D53Q35939808-1C89137D-1343-43B1-AA25-81738DE4DE07Q36073758-DA730DBA-FD49-4196-BFF4-D9DD1DD9DE4DQ36308910-55058BA4-E783-48D8-A418-3E7786136D14Q36319536-9AA85EDC-E2B4-4253-8669-3124320BF704Q36398679-CC7F07D0-9BA3-4635-809A-DB118E776BD2Q36478873-D60258DB-6D7E-47A1-BEEB-546DF1938464Q36478875-0565A0E5-FE5E-42E5-8C67-82913FF63F69Q36521077-42B234CB-8530-4027-8109-B843ECB3ECA2Q37190537-34982147-9FE6-43FE-92C3-94505D36272BQ37253915-8997F4BA-4014-4B66-B210-C463DA81B092Q37740015-0A7D05FD-1FF0-4973-B2C3-CD4DA9227421Q38010460-79BB78A6-F4A2-47B8-BACD-EB0573E44F33Q38031223-0102A248-5F83-4BAD-8610-77BEF4D318FDQ38032920-4CF9EDEC-CED5-42EC-9A6A-71D753A748CBQ38547448-C938BA33-0B16-47F1-830E-3E528A1A55DAQ42048615-22CA8949-05BE-40B3-9BA4-CE2A431CBEC6Q42365931-6D3CA6F3-736A-434B-8A96-B802C3A95D4EQ43944832-3F1CABAD-736A-4AC3-BE4D-5474C7BC2219Q44080551-9F8347EF-27C9-46D3-A426-35EFD0530247Q44343589-30415FF2-0D17-40C6-8E93-E91A516C3DA2Q44371344-26F4715B-9579-412C-A986-5CA659706AB3Q44488917-14B78385-06FA-4351-865A-4ECC13E89FE6Q45264304-15ACF10D-FE54-42C6-9E28-26210D226657Q46522095-E2041D44-7152-400E-A112-A41B350EE0E3Q46539046-8F19C7D5-AA10-415F-8446-D1EC5179E2CEQ46552861-1D1AFA7A-8940-4546-943A-DFCF3213E443Q46946133-42064755-FA9A-4022-8FD1-0BE0D9F1E13CQ47344490-EF0749B7-918E-4DB5-854F-B51C76ED9B33
P2860
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@en
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@nl
type
label
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@en
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@nl
prefLabel
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@en
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@nl
P2093
P2860
P1476
Bedtime H2 blockers improve no ...... nts on proton pump inhibitors.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2036.2001.01050.X
P407
P50
P577
2001-09-01T00:00:00Z